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Background: Restin belongs to MAGE superfamily and is known as MAGE H1. Restin was firstly cloned from HL-60 cells
treated with all-trans retinoic acid (ATRA). Previous studies showed a pro-apoptotic role of Restin in several cell lines.
However, little information is available on its expression patterns and functions in vivo. Our study was performed to
detect if Restin plays a role in breast cancer cells in vitro and in vivo.
Methods and results: Real-time PCR and western blot were conducted to detect Restin expression in multiple breast
cancer cell lines and Restin level was negatively related with cell motility. Restin overexpression and knockdown stable
cell lines were established by transducing lentivirus into MCF-7 and MDA-MB-231 cells. Cell morphology, wound closure
assay, transwell migration and invasion assays were performed to detect if Restin inhibited EMT. Our data showed that
Restin overexpressed cells exhibited classical epithelial cell morphology, and Restin overexpression resulted in activation
of epithelial markers and suppression of mesenchymal markers, and inhibition of cell migration and invasion. Tumor
xenograft model was used to characterize the biological functions of Restin in vivo. We found that Restin overexpression
led to reduced lung metastasis. Real-time PCR, western blot, luciferase assay and ChIP assay were performed to identify
the potential targets of Restin and the underlying molecular mechanisms. Among several master regulators of EMT, only
ZEB1/2 levels were dramatically inhibited by Restin. Unexpectedly, Restin indirectly regulated ZEB1/2 expression
at post-transcriptional level. We further identified mir-200a/b, well-characterized mediators controlling ZEB1/2
expression, were transcriptionally activated by Restin and the regulation was dependent on the p53 binding site
in mir-200b/a/429 promoter. Further mechanical studies demonstrated Restin interacted with p73, one of p53
family members, which contributed to Restin-mediated activation of mir-200a/b and suppression of ZEB1/2.
Conclusions: Taken together, our results suggest that Restin inhibits EMT and tumor metastasis by controlling the
expression of the tumor metastasis suppressor mir-200a/b via association with p73. Our findings not only establish a
mechanistic link between Restin, EMT and tumor metastasis, but also provide strong evidence supporting the notion
that MAGE Group II proteins may exert a tumor suppressive effect in vivo.
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The melanoma-associated antigen (MAGE) is one of the
well-characterized members of the CTA family that con-
tains at least 60 closely related proteins [1], including
MAGE-A, B, C, D, E, F, G, H, L2, Necidin, I and J. Accord-
ing to the protein expression patterns and functions, the
MAGE family has been divided into groups I and II [2,3].
Group I proteins, including MAGEs A, B and C, are
expressed in many types of tumor tissues, but are not
expressed in normal tissues [1]. Moreover, their expression
is closely correlated with aggressive clinical course, the ac-
quisition of resistance to chemotherapy, the occurrence,
and poor clinical outcomes [1,3,4]. Contrast to group I
proteins, Group II proteins, such as Necdin and Mage-D1,
are universally expressed in all normal tissues but rarely in
tumor tissues [5]. They are more likely associated with cell
growth inhibition, cell cycle arrest, apoptosis, or cell differ-
entiation [6]. For example, Necdin has been shown to be
down-regulated in both carcinoma cell lines and primary
tumors [7-9], suggesting Necdin is a potent tumor growth
suppressor. Ectopic overexpression of Necdin in a mouse
tumor cell line is reported to attenuate tumorigenicity and
metastasis in vivo [10]. In addition, MAGE-D1 inhibited
cell proliferation, migration and invasion of multiple human
cancer cells [11]. Although Group II proteins emerge as
novel tumor suppressor candidates in a wide range of hu-
man cancers, their roles in cancers remain poorly defined.
Restin belongs to MAGE Group II proteins and is
known as MAGE H1 [12]. Restin was firstly cloned from
the differentiated HL-60 cells induced by all-trans retin-
oic acid (ATRA) [13], an apoptosis and differentiation
inducer. Bioinformatics analysis showed that Restin
shared 49% homology with Necdin [14] and both of
them were basic proteins. Further analysis found that
Restin, Necdin and Mage-D1 had an alkaline conserva-
tive region, which is lowly expressed in tumor tissues
[14]. Above data indicated that, similar to Necdin and
Mage-D1, Restin belongs to Group II proteins. Bioinfor-
matics data from GEO profiles show that Restin is rarely
expressed in a variety of cancer cells, while its expression
level is pretty high in normal cells. Restin was identified
as one of pro-apoptotic genes that determined the re-
sponse of multiple tumor cells to CD95-mediated apop-
tosis [15]. Fu HY et al. found that Restin overexpression in
Hela cells promoted apoptosis [16]. Denis Selimovic et al.
disclosed that Restin overexpression induced apoptosis
of melanoma cells via interacting with p75 neurotrophin
receptor (p75NTR), leading to the disruption of both
NF-ƘB and extracellular signal-regulated kinase (ERK)
pathways [12]. Thus, Restin may function as a tumor
suppressor, which is similar to Necdin and Mage-D1.
Nevertheless, little information is available on its ex-
pression patterns and functions, particularly its roles in
tumorigenesis in vitro and in vivo.The epithelial-mesenchymal transition (EMT) and the
reverse process, termed the mesenchymal-epithelial
transition (MET), play critical roles in embryogenesis,
wound healing, tissue fibrosis, and carcinoma progres-
sion [17-20]. EMT is known to be a central mechanism
responsible for invasiveness and metastasis of a variety
of cancers [19-21]. During tumor development, epithelial
cells undergo dynamic cytoskeletal rearrangement, and lose
cell adhesion and epithelial components while acquiring
mesenchymal and migratory phenotypes [20,22]. There-
fore, targeting EMT may serve as an efficient strategy for
the treatment of malignant and metastatic tumors.
Our present study, for the first time, demonstrated that
Restin remarkably suppressed breast cancer metastasis
through inhibiting EMT by controlling the expression and
function of the tumor metastasis suppressor mir-200a/b
via association with p73 in breast cancer cells.
Results
Restin expression level was negatively related with tumor
cell mobility
Previous study showed that Restin overexpression in-
duced apoptosis of melanoma cells [12], indicating Res-
tin may be associated with cell malignancy. Thus, we
first tested if Restin overexpression inhibited cell pro-
liferation in two breast cancer cell lines. Contrast to
melanoma cells, Restin overexpression failed to inhibit
cell proliferation determined by 3[H] incorporation assay
(Figure 1A). Next, we detected if Restin was related with
cell mobility, another tumor cell malignant feature. To
test this, Restin expression level was determined in non-
metastatic, low-metastatic and high-metastatic cells. As
expected, Restin mRNA level was pretty high in two
non-metastatic cells, MCF-10A and HMEC, while it was
moderately decreased in low-metastatic MCF-7 cells
(Figure 1B). However, Restin was barely detectable in
high-metastatic MDA-MB-231 and MDA-MB-451 cells
(Figure 1B). Restin protein levels showed the similar
trend (Figure 1C). TGF-β is a strong inducer of cell mobil-
ity in epithelial cells [23]. As expected, Restin expression
level was gradually decreased upon TGF-β treatment in
MCF-7 cells (Figure 1D). Above data indicated that
Restin expression level is negatively related with tumor
cell mobility.
Restin prevented EMT in breast cancer cells
EMT is a crucial program for the invasion and metasta-
sis of epithelial tumors that involves loss of cell-cell ad-
hesion and increase of cell mobility [19-21]. To examine
if Restin plays a role in EMT process, cell morphology
and EMT markers were detected. Restin overexpression
and knockdown stable cell lines were generated in
MDA-MB-231 and MCF-7 cells and Restin expression
levels were confirmed by western blot (Additional file 1:
Figure 1 Restin expression level was negatively related with tumor cell mobility. (A) Restin overexpression failed to inhibit cell proliferation
determined by [3H] thymidine incorporation assay. MCF-7 and MDA-MB-231 (2 x 104) cells were seeded onto 24-well plates. [3H] thymidine
(1 mCi/well) was added 4 hours before the termination of experiment. Data were represented as the means ± S.M. of three independent
experiments. mRNA (B) and protein (C) levels of Restin were determined by RT-PCR and western blot. MCF-10A, HMEC, MCF-7, MDA-MB-231
and MDA-MB-451 cells (1 x 105) were seeded onto 6-well plates. Values were expressed as means ± S.M. of at least three independent experiments. (D)
Restin expression in MCF-7 cells upon TGF-β treatment was determined by western blot. MCF-7 cells (5 x 104) were seeded onto 6-well plates and TGF-β
(5 ng/ml) were added for 6 days. Tubulin was used as a loading control. Results presented here are representative of three different experiments.
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their elongated spindle-like morphology with sharp bor-
ders (Figure 2A). However, Restin overexpressed MDA-
MB-231 cells displayed a cobblestone-like epithelial
phenotype, grew as a monolayer and formed islands
of grouped cells with tight cell-cell contact (Figure 2A).
In addition to morphological changes, the expression
levels of critical genes for EMT process were deter-
mined. E-cadherin plays a central role in maintaining
epithelial cell-cell adhesion and polarity [24]. Real-time
PCR showed a remarkable increase in E-cadherin ex-
pression in Restin overexpressed cells (Figure 2B). The
concomitant increase in ZO-1 expression was observed
either. In contrast, Restin overexpresssion resulted in a
strong repression on the expression of mesenchamal
markers, including N-cadherin, Vimentin and Fibronec-
tin, in MDA-MB-231 cells (Figure 2B). Similar results
were confirmed by western blot analysis (Figure 2C).
Thus, morphological alteration from a fibroblastic to an
epithelial phenotype and an increase of E-cadherin level
upon Restin overexpression strongly indicate that Restin
inhibits EMT process. Furthermore, we determined ifknockdown of Restin promoted EMT. To this end, cell
morphology and EMT markers were tested upon Restin
knockdown in low-mobility MCF-7 cells. Although knock-
down of Restin failed to change cell morphology (data not
shown), these cells apparently exhibited a spindle-like
morphology upon TGF-β induction (Figure 2D). Consist-
ently, E-cadherin and ZO-1 expression were signifi-
cantly inhibited, whereas Vimentin and Fibronectin
expression were moderately enhanced in Restin knock-
down cells as compared to si-Control group (Figure 2E).
Our data suggest that Restin inhibits EMT in breast
cancer cells.
Restin suppressed migration and invasiveness of breast
cancer cells
Fibroblast cells that have undergone MET are characterized
by their decreased motility and loss of invasiveness. There-
fore, we detected whether Restin overexpression resulted in
decreased motility of MDA-MB-231 and MDA-MB-451
cells determined by wound closure assay, transwell migra-
tion and invasion assays. As shown in Figure 3A, the per-
centage of wound closure for Control MDA-MB-231 cells
Figure 2 Restin prevented EMT in breast cancer cells. (A) Morphologic changes in MDA-MB-231 cells upon Restin overexpression. Phase-contrast
cell images were taken (×40 magnification). mRNA (B) and protein levels (C) of epithelial markers (E-cadherin and ZO-1) and mesenchymal
markers (Fibronectin, N-cadherin and Vimentin) in MDA-MB-231 cells (Control and Restin overexpression) were determined by real-time PCR and
western blot. Values were expressed as means ± S.M. of at least three independent experiments. * p < 0.05 vs Control group. Tubulin was used as
a loading control. Results presented here were representative of three different experiments. (D) Morphologic changes in MCF-7 cells upon Restin
knockdown plus TGF-β treatment. MCF-7 cells (si-Control and si-Restin) were seeded onto 6-well plates and TGF-β (5 ng/ml) were added for
6 days. Phase-contrast cell images were taken (×40 magnification). (E) Protein levels of epithelial markers (E-cadherin and ZO-1) and mesenchymal
markers (Fibronectin, N-cadherin and Vimentin) in MCF-7 (si-Control and si-Restin) cells were determined by western blot. Tubulin was used as a
loading control. Results presented here were representative of three different experiments. Restin: Restin overexpression; si-Restin: Restin knockdown.
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7.43% wound closure, suggesting that Restin severely de-
stroys the migration ability of MDA-MB-231 cells. Consist-
ently, Restin overexpression significantly inhibited the
number of migrating cells (43.46% and 40.47% inhibition in
MDA-MB-231 and MDA-MB-451 cells, respectively) com-
pared with Control cells (Figure 3B). Next, we performed
transwell matrigel invasion assay to assess whether Restin
inhibited cell invasiveness. As shown in Figure 3C, Restin
overexpression caused a reduction of invasive cells by more
than 41.65% and 37.61% in MDA-MB-231 and MDA-MB-
451 cells compared with their Control cells. We also found
that Restin overexpressed cells displayed significantly less
adherence to fibronectin compared with Control group
(Figure 3D). These results suggest that Restin suppresses
cell migration and invasiveness of metastatic breast cancer
cells.
Restin inhibited lung metastasis in vivo
In order to evaluate if Restin-mediated inhibition of EMT
indeed plays a role in vivo, tumor growth and lung metas-
tasis were monitored in NOD-SCID mice implanted with
Control and Restin overexpressed MDA-MB-231 cells.The tumor growth rate showed no statistic difference
between Control and Restin overexpression groups
(Figure 4A, p > 0.05). Consistently, the tumor size was
similar in the two groups (Figure 4B). Interestingly, the
tumors formed by Control MDA-MB-231 cells gave rise
to 13.32 ± 1.659 metastatic nodules per lung (Figure 4C).
However, Restin overexpression resulted in a 2.7-fold de-
crease of lung metastases (Figures 4C and D). Our in vivo
data indicate that the morphological changes caused by
Restin overexpression is closely related to decreased lung
metastasis.
Restin downregulated ZEB1/2 expression at
post-transcriptional level
Downregulation of E-cadherin is one of the critical
markers of EMT in human breast cancers [25]. FOXC2,
Twist, ZEB1, ZEB2, Slug and Snail are identified transcrip-
tion factors that repress E-cadherin transcription and
overexpression of each gene induces EMT and promotes
malignant cell invasion and dissemination [21,24]. Consid-
ering the positive regulation of Restin on E-cadherin, we
hypothesize that Restin may control the expression of
those transcription factors. We found that the expression
Figure 3 Restin overexpression inhibited migration and invasiveness of breast cancer cells. (A) Scratch wound healing assay of MDA-MB-231 cells.
5 × 105 MDA-MB-231 cells (Control and Restin overexpression) were seeded onto 6-well plates. The 6-well plates were scratched (time 0) and 20
random fields of view per well were photographed after 12 h of scratch. Representative pictures from 3 independent experiments were shown.
The motility of MDA-MB-231 and MDA-MB-451 cells was evaluated by transwell migration (B) and Matrigel invasion assays (C) as described in the
Materials and Methods. Migration was quantitated by counting 10 fields at a magnification of × 400. Data were presented as the average number
of migrated cells from three independent experiments. * p < 0.05 vs Control group. (D) Adhesion capacity of MDA-MB-231 and MDA-MB-451 cells
was measured by cell attachment assay. MDA-MB-231 and MDA-MB-451 cells (Control and Restin overexpression) were seeded onto 96-well
plates pretreated with fibronectin for 30 min at a density of 2 × 103 cells/well in triplicate. Cells were allowed to adhere for 2 h and adherent cells
were stained with crystal violet and quantified using the absorbance as a measurement at 550 nm. Values were expressed as means ± S.M. of at
least three independent experiments. * p < 0.05 vs Control.
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76.4% and 70.0%, respectively, upon Restin overexpression
(Figure 5A). However, a slight reduction in Twist, Snail
and Slug mRNA levels was observed (Figure 5A). Consist-
ently, ZEB1 and ZEB2 protein levels were apparently
inhibited by Restin overexpression (Figure 5B). However,
no apparent difference was observed in Twist and Slug
protein levels. On the contrary, Restin knockdown re-
sulted in a dramatic increase in ZEB1 and ZEB2 levels,
while only a marginal effect on Twist and Slug expression
(Figure 5C, lane 3 versus lane 1). Consistent with TGF-β-
mediated negative regulation on Restin, TGF-β treat-
ment further enhanced ZEB1 and ZEB2 expression levels
(Figure 5C, lane 4 versus lane 2).
Next, we determined if ZEB1/2 was involved in
Restin-mediated inhibition of EMT. E-cadherin, Vimen-
tin and Fibronectin levels were tested upon ZEB1 knock-
down (Additional file 1: Figure S2). Control MCF-7 cells
transfected with ZEB1 siRNAs showed moderately
enhanced E-cadherin and decreased Vimentin and
Fibronectin expression (Figure 5D, lane 2 relative to lane 1),
which is consistent with ZEB1 function in promoting EMT.Restin knockdown led to reduction of E-cadherin and
increase of Vimentin and Fibronectin (Figure 5D, lane
3 relative to lane 1). Additional knockdown of ZEB1 ef-
fectively reversed the expression of these proteins, and
their levels were comparable to that in Control cells
(Figure 5D, lane 4 relative to lane 2). Collectively, these
data indicate that ZEB1 is a crucial mediator of Restin-
induced phenotypes.
Previous studies showed that Restin was localized in
nucleus and it interacted with several transcription fac-
tors [26,27], indicating it may regulate ZEB1 expres-
sion at the transcriptional level. To test this, ZEB1
promoter activity was detected by luciferase reporter
assay. We found that Restin overexpression failed to acti-
vate the transcription of ZEB1 (Figure 5E). Since Restin
suppressed ZEB1 and ZEB2 mRNA levels, it is possible
that Restin may regulate ZEB1 expression at the post-
transcriptional level. As expected, Restin overexpression
strongly repressed the luciferase activities driven by ZEB1
3’UTR in a dose-dependent manner (Figure 5F). Further-
more, an enhanced luciferase activity was observed upon
Restin knockdown (Additional file 1: Figure S3).
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downregulation of ZEB1
Accumulating evidences demonstrate that mir-200 family
is a powerful microRNA family controlling ZEB1/2 ex-
pression [23,28]. To determine if mir-200 members are in-
volved in Restin-mediated downregulation of ZEB1/2,
mir-200a, mir-200b, mir-429, mir-200c and mir-141 levels
were determined upon Restin overexpression and knock-
down. As shown in Figure 6A, overexpression of Restin
significantly enhanced mir-200a and mir-200b expression
by 2.71- and 2.07-fold, while their levels were greatly
inhibited by Restin knockdown (Figure 6B), hinting that
Restin may regulate the transcription of mir-200b/a/429.
However, the expression levels of mir-200c and mir-141,
which are located in another genomic cluster, were not
altered by Restin overexpression (Additional file 1:
Figure S4). Our hypothesis was further confirmed by
luciferase reporter assay showing that Restin signifi-
cantly increased the luciferase activity driven by mir-
200b/a/429 promoter but not mir-200c/141 promoter
(Figure 6C and Additional file 1: Figure S5). Next we
determined if mir-200b/a is indeed responsible for
Restin-mediated downregulation of ZEB1 and ZEB2. To
this end, a mutant ZEB1 3’UTR with deletion of mir-
200b binding sites was constructed. Consistent with
above data, Restin overexpression decreased the lucifer-
ase activities driven by ZEB1 3’UTR, while failed to re-
duce the luciferase activities driven by mutant ZEB1
3’UTR (Figure 6D).
Restin activated mir-200b/a/429 transcription in a
p73-dependent manner
To investigate the molecular mechanisms by which Restin
upregulated mir-200b/a transcription, a series of mir-200b/
a/429 promoter truncations were constructed (Figure 7A)
and their luciferase activities were determined. As shown
in Figure 7B, Restin dramatically enhanced the luciferase
activities driven by WT mir-200b/a/429 promoter (P1,-
1574/+120). However, Restin failed to activate the mir-
200b/a/429 promoter activities with deletion of p53 binding
sites (-1412/-1408) in P2 truncation (-1000/+120) and an-
other two shorter truncations (P3 and P4). Above data sug-
gest that p53 binding site is critical for Restin-mediated
activation of mir-200b/a/429 transcription. To further dem-
onstrate this, we introduced a luciferase reporter construct
in which the p53 binding site had been mutated (Figure 7C,
bottom panel). As expected, the luciferase activities driven
by WT mir-200b/a/429 promoter was increased by 1.69-
fold upon Restin overexpression, whereas Restin was
unable to upregulate the activities of mir-200b/a/429 pro-
moter with mutations in p53 binding site (Figure 7C).
These data indicate that Restin directly or indirectly acti-
vates the transcription of mir-200b/a/429 through p53
binding site on its promoter.The p53 family comprises three genes that encode for
p53, p63 and p73 [29]. To identify which factor is involved
in Restin-activated mir-200b/a/429 transcription, the ex-
pression levels of three proteins were first detected in sev-
eral breast cancer cell lines. It is well-documented that
MCF-7 cells contain wild-type p53, MDA-MB-231 cells
carry mutant p53 with greater levels, and MDA-MB-157
cells expressed no p53 [30]. As shown in Figure 7D, p53
was moderately expressed in MCF-7 cells, and was un-
detectable in MDA-MB-157 cells, whereas a high level of
mutant p53 protein was observed in MDA-MB-231 cells.
All cell lines were negative for p63 (data not shown),
whereas contained detectable and comparable p73 levels
(Figure 7D). It has been demonstrated that MDA-MB-231
cells have mutant p53 due to an arginine to lysine mutation
at position 280 and the mutant p53 does not retain the
tumor suppressive ability of wild-type p53 [30]. We com-
pared the luciferase activities driven by mir-200b/a/429
promoter in above three cell lines and found that Restin ac-
tivated the luciferase activities in a comparable manner
whatever the expression level and function of p53 in those
cells (Additional file 1: Figure S6). Therefore, we postulate
that p53 may not participate in Restin-mediated transcrip-
tional activation of mir-200b/a/429. Considering the un-
detectable level of p63, we hypothesize that p73 may play a
role in Restin-mediated upregulation of mir-200b/a. To test
this, reciprocal co-immunoprecipitation was performed to
detect the interaction between p73 and Restin. HERK-293
cells were transiently transfected with Flag-tagged Restin
and His-tagged p73 plasmids. Upon immunoprecipitation
of p73 using an anti-His antibody, Restin was coimmuno-
precipitated (Figure 7E, upper panel). Likewise, in the
immunoprecipitate of Flag-Restin, p73 protein was recov-
ered (Figure 7E, lower panel). Endogenous interaction of
p73 and Restin was also examined in MCF-7 cells. Anti-
Restin antibody could co-immunoprecipitate endogenous
p73 (Additional file 1: Figure S7). As expected, endogenous
interaction between p53 and Restin was not found in
MCF-7 cells determined by co-immunoprecipitation assay
(Additional file 1: Figure S8).
Next we investigated if Restin upregulated mir-200b/a
transcription in a p73-dependent manner. siRNAs medi-
ated p73 knockdown was confirmed by western blot
(Additional file 1: Figure S9). In MDA-MB-231 Control
cells, knockdown of p73 inhibited the luciferase activities
driven by mir-200b/a/429 promoter by 0.69-fold, sug-
gesting that p73 indeed regulates the transcription of
mir-200b/a/429 (Figure 7F, lane 2 relative to lane 1). In
Restin overexpressed cells, the luciferase activity was
dramatically increased by 3.20-fold compared to Control
cells (Figure 7F, lane 3 relative to lane 1). However, its
activity was significantly decreased by 2.93-fold upon
p73 knockdown (Figure 7F, lane 4 relative to lane 3) and
reached to the level exhibited by Control cells plus p73
Figure 4 Restin overexpression inhibited lung metastasis in vivo. (A) The volume of primary tumors was measured after the transplantation of
Control and Restin overexpressed MDA-MB-231 cells. 1 × 105 MDA-MB-231 cells were subcutaneously injected into the mammary fat pad of
immunocompromised NOD/SCID mice (n = 5). Tumor growth was monitored every 4 days. Data were shown as mean size ± S.M. of tumors in
five mice per cell line. Animal experiments were repeated three times. (B) Xenograft tumor size from NOD/SCID mice grafted with Control
and Restin-overexpressed cells. (C) The metastatic nodules in the lungs were counted following the orthotopic transplantation of Control and
Restin overexpressed MDA-MB-231 cells. Values were expressed as means ± S.M. in five mice. * p < 0.05 vs Control. (D) Representative HE
staining of lung metastases. Arrows indicate micrometastases.
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ently, we found that p73 knockdown slightly decreased
mir-200a/b expression level which was apparently en-
hanced by Restin overexpression (Figure 7G). However,
p73 knockdown remarkably diminished mir-200a/b ex-
pression to the similar level as seen in the MDA-MB-231
Control cells (Figure 7G). To further confirm the contribu-
tion of p73 to Restin-mediated regulation of mir-200b/a,
levels of ZEB1/2, targets of mir-200b/a, were evaluated
upon p73 knockdown. Although Restin overexpression ap-
parently inhibited ZEB1/2 expression (Figure 7H, lane
3 relative to lane 1), p73 knockdown almost restored
ZEB1/2 expression to the levels observed in Control
cells (Figure 7H, lane 4 relative to lane 2), suggesting
that p73 is a critical mediator for Restin-induced upre-
gualtion of mir-200b/a and downregulation of ZEB1/2.
Discussion
MAGE group II proteins function as putative tumor sup-
pressors in a variety of cancers [5,6]. However, its clinical
effects on tumor development and the underlying mecha-
nisms are poorly characterized. Restin is a novel member
of MAGE group II proteins [12]. Selimovic et al. demon-
strated Restin induced apoptosis of melanoma cells via
interaction with p75 neurotrophin receptor [12]. Wang
et al. showed that p53 upregulated Restin expression at
the transcriptional level [31]. All current data hint thatRestin may be involved in tumor cell growth. Neverthe-
less, the molecular mechanisms underlying the repres-
sion of Restin in tumor cells and its role in tumor
development had not been reported yet. Here, we, for
the first time, showed that Restin suppressed EMT and
lung metastasis by activating the transcription of mir-
200b/a via association with p73. Considering the pivotal
roles of mir-200b/a and p73 in tumorigenesis, our stud-
ies provide significant insights that Restin may partici-
pate in other functions closely related to mir-200b/a
and p73, such as EMT, cancer stem cells, tumor angio-
genesis and drug resistance.
mir-200 family plays critical roles in tumor develop-
ment and progression through inhibiting EMT and sup-
pressing tumor invasion by directly repressing the
transcription factors ZEB1 and ZEB2 [23,28,32,33]. Pre-
vious works on mir-200 regulation have largely focused
on mechanisms of transcriptional inhibition, epigenetic
modification and transcriptional activation of this
miRNA family, and identified multiple factors regulating
mir-200 expression, including ZEB1, ZEB2, HDAC, p53
family [32]. Our study demonstrated that Restin upregu-
lated mir-200 expression at the transcriptional level,
indicating Restin may serve as a novel regulator of mir-
200. However, Restin-mediated upregulation of mir-
200b/a/429 was dependent on p53 binding site in its
promoter, indicating p53 family members (p53, p63,
Figure 5 Restin downregulated ZEB1/2 expression at the post-transcriptional level. RNA (A) and protein levels (B) of FOXC2, Twist, ZEB1, ZEB2,
Slug and Snail in Control and Restin overexpressed MDA-MB-231 cells were determined by real-time PCR and western blot. Values were expressed
as means ± S.M. of at least three independent experiments. * p < 0.05 vs Control group. (C) Expression level of above proteins in si-Control
and si-Restin MCF-7 cells treated with TGF-β was determined by western blot. Tubulin was used as a loading control. Results presented
here were representative of three different experiments. (D) MCF-7 stable cells (si-Control and si-Restin) were seed onto 6-well plates and
transfected with control and ZEB1 siRNAs (si-ZEB1). 48 h posttransfection, proteins were collected and western blot was performed to detect
protein levels of E-cadherin, Fibronectin and Vimentin. Tubulin was used as a loading control. Result presented here was a representative of
three different experiments. (E) ZEB1 promoter activity was determined by luciferase reporter assay. HEK293 cells were seeded in 24-well
plates and transfected with Restin overexpression lentivirus and ZEB1 promoter plasmids. The firefly luciferase activity was normalized to
that of the renilla luciferase. (F) ZEB1 3’UTR activity was determined in HEK293 cells by luciferase reporter assay upon Restin overexpression.
HEK293 cells were seeded in 24-well plates and transfected with ZEB1 3’UTR plasmids and different dose of Restin overexpression lentivirus.
The firefly luciferase activity was normalized to that of the renilla luciferase. Values were expressed as means ± S.M. of at least three
independent experiments. * p < 0.05 relative to cells without addition of lentivirus (−), # p < 0.05 relative to Control group.
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by transactivating the expression of mir-200 family
members in primary hepatocellular carcinomas (HCCs)
and 9 HCC cell lines [34]. Simlar to p53, p73 and p63can directly associate with the mir-200b/a/429 promoter
and activate mir-200 transcription in ovarian carcinoma
cells [35]. Although MDA-MB-231 cells or MDA-MB-
157 cells possess mutant p53 or no p53 expression,
Figure 6 mir-200b/a was responsible for Restin-mediated downregulation of ZEB1. RT-PCR was performed to detect mir-200a and mir-200b levels
in Restin overexpressed MDA-MB-231 cells (A) and Restin knockdown MCF-7 cells (B). Values were expressed as means ± S.M. of at least three
independent experiments. * p < 0.05 relative to Control or si-Con group. (C) mir-200b/a/429 promoter activity was determined in HEK293 cells by
luciferase reporter assay. HEK293 cells were seeded ontn 24-well plates and transfected with mir-200b/a/429 promoter plasmids and different
dose of Restin overexpression lentivirus. The firefly luciferase activity was normalized to that of the renilla luciferase. Values were expressed as
means ± S.M. of at least three independent experiments. * p < 0.05 relative to cells without addition of lentivirus (−), # p < 0.05 relative to their
Control group. (D) ZEB1 3’UTR (WT and mutant) activity was determined by luciferase reporter assay upon Restin overexpression. WT and mutant
ZEB1 3’UTR with deletion of mir-200 binding sites were transfected into HEK293 cells. 24 h later, different dose of Restin overexpression lentivirus
were added. The firefly luciferase activity was normalized to that of the renilla luciferase. Values were expressed as means ± S.M. of at least three
independent experiments. * p < 0.05 relative to cells without addition of Restin lentivirus.
Lu et al. Molecular Cancer  (2015) 14:102 Page 9 of 14Restin still activated mir-200b/a/429 transcription, indi-
cating p53 protein may not participate in above process
and Restin may not associate with p53. Our hypothesis
was proven by our data showing that no endogenous
interaction between Restin and p53 was found. By per-
forming Co-IP experiment, we found that Restin can
closely interact with p73. Moreover, p73 knockdown di-
minished Restin-mediated regulation on mir-200a/b and
ZEB1/2. Thus, our observations provide new insights
into the role of p53 family members in mediating Res-
tin’s function in tumorigenicity.
Based on the chromosomal locations, the mir-200
family can be divided into two clusters: the mir-200b/a/
429 cluster containing mir-200a, mir-200b and mir-429,
and the mir-200c/141 cluster, which contains mir-200c
and mir-141 [32]. Although both clusters contained pu-
tative p53 binding sites, Restin drove mir-200b/a/429
transcription rather than that of mir-200c/141 via associ-
ation with p73. Interestingly, a recent report found that
in mammary epithelial cells, p53 serves as a transcrip-
tional activator of mir-200c/141, but not of the mir-
200b/a/429 [36]. We speculate that the transcription of
mir-200 clusters by p53 family members may be dependent
on the expression level and functions of p53 familymembers, the promoter methylation status of mir-200 pro-
moters or other transcriptional co-factors, which need to
be further elucidated.
p53 is involved in tumor initiation as well as tumor
progression [37-39]. However, deletions or mutations of
p53 are frequently found in cancers [39-43]. p63 and
p73 are rarely mutated in a large number of tumors ex-
amined to date [42]. Therefore, in the absence of p53,
these proteins may be involved in the control of the
ZEB/mir-200 equilibrium and EMT-MET plasticity. Our
data showed that Restin interacted with p73 rather than
p53 and upregulated mir-200b/a expression even in p53
mutant cells. Our results shed light on the transcriptional
regulation of Restin on mir-200s, which has potential
therapeutic value in the development of approaches aimed
at modifying mir-200s expression for the treatment of di-
verse forms of human cancers, especially those cancers
with p53 mutation.
Restin was identified from HL-60 cells induced by all-
trans-retinoic acid (ATRA). Restin expression level was un-
detectable in HL-60 cells, whereas its level was sharply
increased upon ATRA treatment [13,14]. Consistently, we
observed that Restin expression was pretty high in normal
breast epithelial cells compared to breast cancer cells. Its
Figure 7 (See legend on next page.)
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Figure 7 Restin activated mir-200 transcription in a p73-dependent manner. (A) A schematic diagram of the human mir-200b/a/429-
luciferase constructs (WT and its truncations) was shown. (B) A series of mir-200b/a/429 promoter activities were determined by luciferase
reporter assay. Restin overexpression lentivirus were added into 293T cells and mir-200b/a/429 promoter truncation plasmids were transiently
transfected. * p < 0.05 relative to Control lentivirus. (C) mir-200b/a/429 promoter (WT and p53 mutant) activities were measured by luciferase
reporter assay. * p < 0.05 relative to Control lentivirus. (D) Western blot was performed to detect p53 and p73 levels in MCF-7, MDA-MB-231 and
MDA-MB-157 cells. (E) Co-immunoprecipitation assay was performed to detect the exogenous interaction between Restin and p73. HERK-293
cells were transiently transfected with Flag-tagged Restin and His-tagged p73 plasmids. (Upper panel) Cell extracts were immunoprecipitated
with mouse IgG or anti-His antibody and then blotted with anti-Flag antibodies. (Lower panel) Cell extracts were immunoprecipitated with
mouse IgG or anti-Flag antibody and then blotted with anti-His antibody. (F) MDA-MB-231 stable cells (Control and Restin overexpression) were
seed onto 24-well plates and co-transfected with Control or p73 siRNAs (si-Con and si-p73) and mir-200b/a/429 promoter construct. * p < 0.05
relative to si-Con group, # p < 0.05 relative to Control cells. (G) MDA-MB-231 stable cells (Control and Restin overexpression) were seed onto
6-well plates and transfected with control and p73 siRNAs (si-Con and si-p73). RT-PCR was performed to detect mir-200a and mir-200b expression
levels. * p < 0.05 relative to si-Con group, # p < 0.05 relative to Control cells. (H) MDA-MB-231 stable cells (Control and Restin overexpression)
were seed onto 6-well plates and transfected with control and p73 siRNAs (si-p73). Western blot was performed to detect ZEB1 and ZEB2 levels.
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high-metastatic cells, hinting that Restin expression level is
negatively related to tumor cell malignancy. Our data was
supported by current evidence showing that Necdin, an-
other member of MAGE group II proteins, was expressed
at a low level in MDA-MB-468 and MDA-MB-231 cells,
but exhibited much higher levle in low-metastatic MCF-7
cells [8]. Contrast to Restin and Necdin, MAGE-A and C,
belong to MAGE group I proteins, exerted an oncogenic
role in breast cancer and exhibited a positive correlation
with tumor malignancy [1,3,4]. Considering the undetect-
able expression of Restin in high-metastatic MDA-MB-231
cells and the dramatic inhibition of tumor metastasis by
Restin overexpression, we hypothesize that Restin may
function as a tumor-suppressor in breast cancers. Our on-
going studies are being performed to detect Restin expres-
sion in normal breast tissues, para-carcinoma tissues and
carcinoma tissues and to statistically analyze the associ-
ation of its expression level with tumor malignant grade,
tumor metastasis, relapse, and clinical prognosis, which
will strongly support our hypothesis.Conclusions
Taken together, our study, for the first time, demon-
strated that Restin strongly inhibited lung metastasis
in vivo, which strongly suggests that Restin may serve as
a potent tumor suppressor in breast cancers although
our study is still in a preliminary stage. Our current data
not only shed a light on the function of Restin in tumor
development in light of its inhibition on EMT process
but also facilitate other researchers to extend or verify
its function in other type of cancers.Materials and methods
Cell culture and reagents
MCF-7, MDA-MB-157, MDA-MB-231 and MDA-MB-
451 breast cancer cells were grown in Dulbecco’s modified
Eagle’s medium (Gibco, Grand Island, NY) supplementedwith 10% fetal bovine serum, 2 mM glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin at 37°C in a hu-
midified atmosphere of 5% CO2. MCF-10A, a spontan-
eously immortalized human breast epithelial cell line,
was maintained in DMEM/F12 medium (Invitrogen Life
Technologies, Carlsbad, CA). Human mammary epithe-
lial cells (HMEC) were cultured in mammary epithelial
cell complete medium (Invitrogen). All cell lines were
obtained from the ATCC. p73 and ZEB1 siRNAs
(Stealth™ siRNAs) were synthesized from Invitrogen
and were dissolved in DEPC-treated H2O at a concen-
tration of 20 pmol/μl as a stock.
Generation of Restin overexpression and knockdown
stable cell lines
Restin coding region was amplified by PCR using MCF-7
cDNA as a template and inserted into PmeI restriction en-
zyme sites of pWPI-GFP lentivirus expression vector by
using the following primers: 5’-gtacgtttaaacatgcctcgggag
cgaaagag-3’ and 5’-gatcgtttaaacttaaggggcggaataacccc-3’.
siRNA duplexes targeting Restin were annealed and
inserted into Mlu1 and Cla1 restriction enzyme sites of




products were confirmed by sequencing. Lentivirus
were produced according to the manufacture’s instruc-
tion. MCF-7 and MDA-MB-231 cells were seeded onn
6-well plates and transduced with 10 μl lentivirus. 24 h
later, transfected cells were trypsinized and reseeded
into 10-cm culture plates. We refer to these cells in the
text as Control and Restin (overexpression), si-Control
and si-Restin (knockdown).
Constructs
The following plasmids were bought from Addgene
(Cambridge, MA). mir-200b-200a-429 promoter (Plasmid
35539: pGL3-1574/+120), mir-200c-141 (Plasmid 35534),
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3’UTR with mutation in mir-200b seeding region (Plasmid
35537: pCI-neo-RL-ZEB1 200bmutx5). ZEB1 promoter
plasmid (HPRM23421) was bought from GeneCopoeia
(Rockville, MD). 2000 bp of mir-200c–141 promoter re-
gion was amplified and inserted into pGL3 vector using
Nhe I and Bgl II sites. A series of mir-200 promoter
truncations were amplified by using mir-200 promoter
plasmid (pGL3-1574/+120) as a template and cloned
into the pGL3-basic (Promega) reporter using Nhe I
and Bgl II sites. The primer sequences were as follows:
pGL3-1000/+120: forward, 5’-gtgctagcGAAAACCGTGGG
GTCCGCTG-3’; pGL3-200/+120: forward, 5’-acgctagc
AAGGTGGGGGCGGGACGGAG-3’; reverse, 5’-ctagatct
CCTGGCACAGGAAGTCAGTTC-3’. Mutation in the
p53 binding site was made by using the Quikchange Multi
site–directed mutagenesis kit (Stratagene, La Jolla, CA)
using the primer pairs 5’-CCAGCTCCCAGGTTTTTCC
CGCCG -3’ and 5’-CGGCGGGAAAAACCTGGGAGC
TGG-3’ (p53 mutant) (the mutation sites were shown in
bold) . Restin and p73 coding regions were amplified
using MCF-7 cDNA as a template and inserted into our
previously recombined pcDNA3.1 (+)-flag and pcDNA3.1
(+)-his vectors, respectively.In vivo animal experiments
NOD/SCID mice were purchased from Beijing HFK Bio-
science CO., LTD (Bejing, China). All animal experiments
were performed under the approval of Institutional Animal
Care and Use Committee (IACUC) at Henan Cancer Hos-
pital (Permit No: 2014ct001). 1 × 106 MDA-MB-231 cells
were resuspended in 20 μl PBS and subcutaneously injected
into the fourth mammary fat pad of 8-week old female
NOD/SCID mice (n=5 mice/group). Primary tumor growth
was evaluated every four days by caliper, and tumor volume
was estimated using the following formula: (L ×W2)/2.
Metastatic growth in the lung was allowed to develop for
6–8 weeks. Primary tumors and lung tissues were fixed in
10% neutral buffered formalin, embedded in paraffin, and
subjected to standard hematoxylin and eosin (H & E)
staining.Transfection and luciferase reporter assay
Cells were seeded onto 24-well plates and transfected with
800 ng of luciferase vectors (ZEB promoter, mir-200 pro-
moter, ZEB 3’UTR (WT and mutant)) per well using Lipo-
fectamine2000 Transfection Reagent (Invitrogen). 50 ng of
pBind plasmids were cotransfected to normalize for trans-
fection efficiency. 24 h later, cells were lysed with PLB
lysing buffer. The luciferase activities were measured
with the dual-luciferase reagent assay kit (Promega,
Madison, WI) according to the manufacturer’s instruc-
tions using the TD-20/20 Luminometer (Turner Designs).All reporter assays are shown as relative luciferase activ-
ities (averaged ratios of Firefly luciferase: Renilla FSE) and
are representative of three experiments.
Quantitative real-time PCR
RNAs were collected using Trizol Reagent (Invitrogen).
Reverse transcription was carried out using 2 μg RNA in a
20 μl reaction volume using the Superscript III Reverse
Transcription Kit (Invitrogen). Real-time PCR was per-
formed with the SYBR® Premix Ex TaqTM (Takara Biotech-
nology, Dalian, China) in 20 μl reactions using ABI PRISM
® 7500 Real-Time PCR System (Applied Biosystems, Grand
Island, NY). GAPDH was used as an internal control. Pri-
mer sequences are listed in the Additional file 1: Table S1.
For mir-200 detection, RNAs were reverse transcribed by
miScript Reverse Transcription Kit (Qiagen, Valencia, CA).
qPCR of mir-200a and 200b was performed using miScript
SYBR Green PCR Kits (Qiagen). mir-200 expression was
normalized with U6.
Western blot
MDA-MB-231 cells were harvested and lysed in a RIPA
buffer containing 50 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate,
and 50 mM NaF. One tablet of protease inhibitor mixture
(Complete Mini, Roche Applied Science) was added just
prior to use. Then 30 μg protein lysates were separated by
12% SDS–PAGE and transferred onto nitrocellulose. After
blocking in a 5% non-fat dried milk solution in washing
buffer containing 10 mmol/l Tris (pH 7.5), 50 mmol/l
NaCl, and 0.02% Tween 20 (TBST), membranes were incu-
bated overnight at 4°C with primary antibodies. After
washed three times with TBST, membranes were incubated
for 1 h with horseradish peroxidase-coupled secondary
antibodies at room temperature. Signals were detected with
the ECL kit (Pierce, Rockford, IL).
Antibodies
The following antibodies were used: rabbit polyclonal
anti-Slug (1:1000), anti-Twist1 (1:500), anti-ZEB1 and
anti-ZEB2 (1:500, Santa Cruz Biotechnology, Santa Cruz,
CA). Rabbit monoclonal anti-E-cadherin (1:1000, Santa
Cruz). Rabbit polyclonal anti-MDM2 (C-18) (1:500, Santa
Cruz). Mouse monoclonal anti-α-tubulin (1:2000) and
anti-fibronectin (1:1000) (Cell Signaling, Danvers, MA).
Mouse monoclonal anti-N-cadherin (1:500), anti-ZO-1
(1:1000) and anti-vimentin (1:1000) (Abcam, Cambridge,
UK). Mouse monoclonal anti-Restin (1:500), anti-His
(1:1500) and anti-Flag (1:2000) (Sigma). Mouse monoclo-
nal anti-p73 (1:1000), anti-p53 (1:1000) and anti-p63
(1:1000) (Abcam). Horseradish peroxidase–conjugated
secondary antibodies were obtained from Amersham
Biosciences.
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Human 293 T cells were seeded onto the 10-cm plates and
cotransfected with Flag-tagged Restin and His-tagged p73
constructs using Lipofectamine2000 Transfection Reagent
(Invitrogen). 2 days after transfection, cells were lysed in
precooled RIPA buffer for 30 min on ice, followed by
15 min of centrifugation. Cell lysates were precleaned with
protein G-Sepharose beads (GE Healthcare) for 30 min at
4°C. After centrifugation at 14,000 rpm at 4°C for 15 min,
cleaned lysates were incubated with either anti-Flag or
anti-His antibody on a rocking platform for 4 h at 4°C. Pro-
tein complexes were immunoprecipitated by incubation
with protein G-Sepharose beads for 30 min at 4°C and then
washed three times with lysis buffer. Immunoprecipitated
proteins were eluted with 50 μl of Laemmli loading buffer
and separated by 10% SDS-PAGE. Protein expression was
evaluated by Western blot analysis with either His or Flag
monoclonal antibodies.Wound closure assay
MDA-MB-231 cells were seeded onto 6-cm cell culture
dishes at a density of 5 × 105. A wound was incised in
the central area of the confluent culture by a 10 μl pip-
ette tip. 12 h after scratch, phase-contrast pictures were
taken by a Nikon microscope using a 10x phase contrast
objective.Cell migration and invasion assays
2 × 104 MDA-MB-231 or MDA-MB-451 cells resuspended
in 200 μl serum-free medium were seeded in the upper
chamber with serum-containing medium in the lower
chamber of 24-well transwell plates (BD Biosciences, San
Jose, CA). After 6 h, the experiment was terminated by
wiping the cells from the wells with a cotton swab and
fixed and stained with 0.05% crystal violet for 2 h. Matrigel
invasion assays were done using the BD BioCoat Matrigel
Invasion Chamber (BD Biosciences). The procedures and
the analyses were the same as those for the transwell
migration assay except for the presence of the Matrigel.Cell adhesion assay
96-well cell culture plates were pretreated with 20 μg/ml
fibronectin at 37°C for 2 h and blocked with 0.5% BSA
solution for 1 h. MDA-MB-231 or MDA-MB-451 cells
were plated onto 96-well cell culture plates at a density
of 1×104 cells/well. Cells were allowed to adhere for
30 min, after which the media were removed and nonad-
hered cells were rinsed away. Adhered cells were fixed
with 4% paraformaldehyde, stained with crystal violet
for 10 min and dissolved in 2% SDS. The absorbance was
measured at 550 nm with an ELISA reader (Bio-Tek,
Winooski, VT).[3H] thymidine incorporation assay
MCF-7 and MDA-MB-231 cells (5 × 104) (control and
Restin overexpressed cells) were seeded onto the 24-
well plates. [3H] thymidine (1 mCi/well) was added
4 hours before the cells were harvested and thymidine
incorporation was measured by scintillation counting
(PerkinElmer, Waltham, MA).
Statistical analyses
Statistical significance of the studies was analyzed by
Student’s t test. Differences with P values of <0.05 are
considered significant.
Additional file
Additional file 1: Table S1. Primers used for quantitative real-time PCR.
Figure S1. Western blot was performed to confirm Restin expression
levels in Restin overexpressed MDA-MB-231 cells and Restin knockdown
MCF-7 cells. Figure S2. Western blot was performed to detect ZEB1
expression levels in cells transfected with negative control and ZEB1
siRNAs. Figure S3. ZEB1 3’UTR activity was determined in HEK293 cells
by luciferase reporter assay upon Restin knockdown. HEK293 cells were
seeded onto 24-well plates and transfected with ZEB1 3’UTR plasmids
and different dose of Restin knockdown lentivirus (si-Restin). Figure S4.
mir-200c and mir-141 levels were determined in Control and Restin
overexpressed MDA-MB-231 cells by real-time PCR. Figure S5. mir-200c/
141 promoter activity was determined by luciferase reporter assay.
Figure S6. mir-200b/a/429 promoter activities were measured by luciferase
reporter assay in multiple cell lines. Figure S7. Co-immunoprecipitation
assay was performed to detect the endogenous interaction between Restin
and p73. (Upper panel) MCF-7 cell extracts were immunoprecipitated with
mouse IgG or anti-p73 antibody and then blotted with anti-Restin antibody.
(Lower panel) Cell extracts were immunoprecipitated with mouse IgG or
anti-Restin antibody and then blotted with anti-p73 antibody. Input, total
cell lysates. Figure S8. Co-immunoprecipitation assay was performed to
detect the endogenous interaction between Restin and p53. MCF-7 cell
extracts were immunoprecipitated with mouse IgG or anti-p53 antibody
and then blotted with anti-Restin (upper panel) and anti-MDM2 (C-18)
antibodies (lower panel). MDM2 p90 is a positive control. Input, total cell
lysates. Figure S9. Western blot was performed to detect p73 expression
levels in cells transfected with negative control and p73 siRNAs.
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